Tilia Fiduciary Partners’s CRISPR Therapeutics CRSP Stock Holding History

Tilia Fiduciary Partners’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-42	Closed	-$2.36K	–	177
2023 Q2	$2.36K	Hold	42	–	–	﹤0.01%	483
2023 Q1	$1.9K	Hold	42	–	–	﹤0.01%	466
2022 Q4	$1.71K	Hold	42	–	–	﹤0.01%	464
2022 Q3	$2K	Hold	42	–	–	﹤0.01%	477
2022 Q2	$3K	Hold	42	–	–	﹤0.01%	469
2022 Q1	$3K	Hold	42	–	–	﹤0.01%	493
2021 Q4	$3K	Buy	+42	New	+$3.67K	﹤0.01%	516

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tilia Fiduciary Partners's CRSP Position: Q3 2023 in Review

Tilia Fiduciary Partners sold out of CRISPR Therapeutics (CRSP) in Q3 2023, closing a stake of 42 shares — an estimated $2.36K sold.

Tilia Fiduciary Partners first reported a position in CRSP in Q4 2021 and held it in 7 quarters. The position peaked at $3K in Q2 2022. 406 funds tracked by Wall St. Rank hold CRSP as of Q3 2023.

Tilia Fiduciary Partners reported no remaining CRISPR Therapeutics position as of Q3 2023 after selling out during the quarter.
Tilia Fiduciary Partners sold 42 CRISPR Therapeutics shares in Q3 2023, an estimated $2.36K.
Tilia Fiduciary Partners first reported a position in CRISPR Therapeutics in Q4 2021 and held it in 7 quarters.
Tilia Fiduciary Partners's CRISPR Therapeutics position peaked at $3K in Q2 2022.
406 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2023.

Based on Tilia Fiduciary Partners's 13F filing for Q3 2023, filed 10 Oct 2023.